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ORIGINAL ARTICLE – MELANOMAS
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ABSTRACT
Background. Guidelines for evidence-based follow-up in
melanoma patients are not available. This study examined
whether a reduced follow-up schedule affects: patient-re-
ported outcome measures, detection of recurrences, and
follow-up costs.
Methods. This multicenter trial included 180 patients
treated for AJCC stage IB-II cutaneous melanoma, who were
randomized in a conventional follow-up schedule group
(CSG, 4 visits first year, n = 93) or experimental follow-up
schedule group (ESG, 1–3 visits first year, n = 87). Patients
completed the State-Trait Anxiety Inventory, cancer worry
scale, impact of events scale, and a health-related quality of
life questionnaire (HRQoL, RAND-36). Physicians regis-
tered clinicopathologic features and the number of outpatient
clinic visits.
Results. Sociodemographic and illness-related character-
istics were equal in both groups. After 1-year follow-up, the
ESG reported significantly less cancer-related stress
response symptoms than the CSG (p = 0.01), and
comparable anxiety, mental HRQoL, and cancer-related
worry. Mean cancer-related worry and stress response
symptoms decreased over time (p\ 0.001), whereas mental
HRQoL increased over time (p\ 0.001) in all melanoma
patients. Recurrence rate was 9 % in both groups, mostly
patient-detected and not physician-detected (CSG 63 %,
ESG 43 %, p = 0.45). Hospital costs of 1-year follow-up
were reduced by 45 % in the ESG compared to the CSG.
Conclusions. This study shows that the stage-adjusted,
reduced follow-up schedule did not negatively affect mel-
anoma patients’ mental well-being and the detection of
recurrences compared with conventional follow-up as
dictated by the Dutch guideline, at 1 year after diagnosis.
Additionally, reduced follow-up was associated with sig-
nificant hospital cost reduction.
The incidence of cutaneous melanoma is rising in most
European countries, probably as a result of increased public
awareness, resulting in an increase in thinner melanomas at
time of diagnosis since the last two decades.1,2 Recently, a
stabilization in incidence has been reported in Australia and
North America.3 Due to early detection and improved staging
with sentinel lymph node biopsy, the 5-year survival rates
reported are 92 % for American Joint Committee on Cancer
(AJCC) stage IB and 53 % for stage IIC melanoma patients.4
Increasing incidence and improved prognosis have resulted in
an increased prevalence of melanoma. Consequently, there
are more melanoma patients in clinical follow-up.5,6
For melanoma, there is currently no consensus on the
adequate frequency of posttreatment follow-up visits, and
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surveillance intervals vary widely worldwide.7–9 Most
contemporary surveillance guidelines recommend inten-
sive follow-up schedules.10–12 Important determinants for
surveillance frequency are patients’ reassurance and anxi-
ety reduction, early detection of recurrences or second
primary melanoma, and evaluation of the quality of surgical
treatment.13–17 Patients’ preferences regarding follow-up
frequency are understudied. However, mixed feelings have
been reported. It seems important to balance patients’
reassurance without inducing additional anxiety.18,19
The majority of melanoma recurrences and second pri-
mary melanomas occur within 3 years after initial
treatment, with an increase in occurrence per AJCC
stage.14,20 Approximately 75 % of the recurrences and
almost 50 % of the second primaries are detected by
patients themselves or their partners instead of by clini-
cians.21,22 Patient education might even enlarge the number
of patient-based detections of recurrent disease.23 This
implies that follow-up visits may currently be scheduled
more frequently than necessary, possibly needlessly bur-
dening patients and health care resources.21,22
There is a need for guidelines with an evidence-based
follow-up frequency. The melanoma follow-up (MELFO)
study was designed to determine whether a stage-adjusted
follow-up schedule adversely affects melanoma patients’
mental well-being and the detection of first recurrences or




This randomized, controlled, multicenter trial was ini-
tiated by the University Medical Center Groningen
(UMCG), conducted in six hospitals in the Netherlands in
accordance with the Declaration of Helsinki, and approved
by the central medical ethics committee (METc2004.127).
Given the nature of the study, it was not possible to blind
participants or physicians/nurse practitioners for group
assignment. The conventional follow-up schedule was
according to Dutch Melanoma guideline recommenda-
tions.11 The experimental schedule was defined with an
overall reduction of 27 % of the number of conventional
schedule visits during the first 5 years after diagnosis,
based on the previously reported annual risk of recurrence
development per AJCC stage: IB 18.4 %, IIA 28.9 %, IIB
41.0 %, IIC 45.2 % (Table 1).21,24
Primary endpoint was patients’ mental well-being.
Secondary endpoints were development of recurrence or
second primary melanoma, the person detecting it, and
total hospital costs.
Patients and Procedure
All patients diagnosed with AJCC stage IB-II cutaneous
melanoma, treated with curative intent between February
2006 and November 2013, were eligible for the study.
Exclusion criteria were age\18 and[85 years, inade-
quate knowledge of the Dutch language, and a history of
previous malignancy. AJCC stage IA patients also were
excluded, as the Dutch Melanoma guideline recommends
only a single follow-up visit after treatment.11 Physicians
or nurse practitioners performing follow-up informed eli-
gible patients about the trial immediately after diagnosis
and asked them to participate. After informed consent was
given, randomization was performed into the conventional
(CSG) or experimental (ESG) follow-up schedule group,
stratified for AJCC stage, in random permuted blocks of
four patients, generated by a validated system (Intrialgra-
tor) with the use of a pseudo–random number generator
and a supplied seed number. Randomization and data
management were performed by the Netherlands Com-
prehensive Cancer Organization (IKNL). The first
questionnaire (at inclusion; T1) and a prestamped return
envelope were then sent to the patient’s home address. All
patients received oral and written information on mela-
noma and instructions on self-inspection of skin and lymph
node bearing areas.25 After 12 months (time point 2; T2),
patients completed questionnaires again, excluding those
with recurrent disease.
Instruments
Patients completed sociodemographic questions, two
self-designed questions regarding follow-up schedule
satisfaction, one on self-inspection, and one on the num-
ber of melanoma related visits to the general practitioner
(GP). Also, they filled in the following validated patient
reported outcome measures (PROMs): (1) the 20-item
State-Trait Anxiety Inventory-state version (STAI-S),
measuring the transitory emotional condition of stress or
tension perceived by respondents.26 Higher scores (range
20–80) indicate greater anxiety; (2) the 3-item cancer
worry scale (CWS), assessing concerns about developing
cancer (again) and their impact on daily functioning.27
Higher scores (range 3–12) indicate more concerns; (3)
the 15-item impact of event scale (IES), assessing the
extent to which people are bothered by memories of a
major life-event in terms of intrusion and avoidance.28
Higher scores (range 15–75) indicate the presence of more
intrusion/avoidance; (4) the mental component summary
(MCS) score of the RAND-36, a health related quality
of life (HRQoL) questionnaire. The MCS score was
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standardized with a mean of 50 and a standard deviation
of 10.29
Surgical oncologists, dermatologists, or nurse practi-
tioners performing follow-up, registered melanoma-related
variables, and the actual frequency of melanoma-related
follow-up visits in the hospital. Follow-up consisted of a
comprehensive patient history and physical examination.
Laboratory testing and diagnostic imaging was only per-
formed in patients suspicious for recurrent disease, as
appropriate.
Total follow-up costs of the first year were calculated for
all participating UMCG-patients. Data were received from
the financial administration of the UMCG.
Statistical Analysis
Power analysis for a two-sided test was performed on
the STAI-state score with a power b = 0.80 and a = 0.05.
The purpose was to falsify the nil-hypothesis: no difference
in STAI-state anxiety between patients in the ESG and the
CSG. A sample size of 89 patients in each group was
required to prove a difference between the groups of a
minimum of 4 points (norm 36.5, standard deviation 9.4).
The effect size of this outcome is 0.42.
Statistical analyses were performed on the question-
naires and physician/nurse-practitioner reports after 1 year
of follow-up, using IBM SPSS statistics version 22 (SPSS
TABLE 1 Frequency of follow-up visits for conventional follow-up schedule, recommended by the Dutch melanoma working party, and
reduced experimental follow-up schedule
Conventional follow-up schedule Experimental follow-up schedule
Years* 1 2 3 4 5 6–10 Years* 1 2 3 4 5 6–10
AJCC stage AJCC stage
IB 4 3 2 2 2 IB 1 1 1 1 1 1
IIA 4 3 2 2 2 1 IIA 2 2 1 1 1 1
IIB 4 3 2 2 2 1 IIB 3 3 2 1 1 1
IIC 4 3 2 2 2 1 IIC 3 3 2 1 1 1
* Years after surgery for primary melanoma
All AJCC Stage IB-II 
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FIG. 1 Flow diagram of inclusion and
randomization
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Inc, Chicago, IL). Patient characteristics were compared
between the groups using t tests and Chi square tests as
appropriate. Repeated measures ANOVAs were used to
examine differences between study groups in PROMs,
change over time, and interaction effects. Effect sizes (ES)
were calculated to examine if significant differences found
were clinically relevant. ES\0.2 were considered negli-
gible, those between 0.2 and 0.49 small, those between
0.50 and 0.79 moderate, and those C0.80 large.30 Statisti-
cal significance was achieved at p\ 0.05.
RESULTS
Patients
Of the 212 patients approached, 5 were not eligible and
27 refused participation (response 87 %). A total of 180
patients were randomized, 93 patients were allocated to the
CSG, and 87 patients to the ESG (Fig. 1). Sociodemo-
graphic and clinicopathologic characteristics were
comparable between groups. Median age was 57.4 years,
51.7 % were females, 37.8 % had completed high educa-
tion (high vocational education or university), 84.4 % had
a partner, 47.2 % had paid employment, and 38.9 %
reported other co-morbidity. Median Breslow thickness
was 1.6 mm. The trunk was more commonly affected in
males (54.0 %) and the lower limbs in females (40.9 %,
p\ 0.001). At 1 year after enrollment (T2), 84.5 % of the
CSG and 94.2 % of the ESG reported being satisfied with
the assigned schedule (p = 0.60). Eight CSG patients
preferred less frequent follow-up, whereas three CSG and
four ESG patients desired more frequent follow-up
(p = 0.02). Fifteen patients had a recurrence: six before T2
and nine just after T2 questionnaire completion (Table 2).
A total of 19 patients (CSG: 11.8 %, ESG: 9.2 %,
p = 0.92) were lost to follow-up at T2. Before T2, six
patients had recurrent disease (of whom 3 died), and two
died of nonmelanoma-related causes. Eleven patients
withdrew from the study before T2 because of dissatis-
faction with the allocated schedule (CSG: n = 5, ESG:
n = 3) or continuation of follow-up in another clinic
(CSG: n = 1, ESG: n = 2). Excluding these 11 patients
plus the 2 deceased of other cause, but including all 15
recurred patients, a total of 44 patients (26.3 %) did not
adhere completely to the assigned follow-up schedule.
Thirteen patients (7.8 %; CSG: n = 10, ESG: n = 3)
attended less outpatient clinic visits than planned, whereas
31 patients (18.6 %; CSG: n = 12, ESG: n = 19) paid
extra visits, due to melanoma-related anxiety or physical
complaints (no significant difference between groups,
p = 0.068). Besides outpatient clinic visits, some patients
also reported melanoma-related visits to the GP.
Summarizing outpatient clinic and GP visits, 26 patients
(30.6 %) in the CSG and 25 patients (30.5 %) in the ESG
paid extra visits during the first year after diagnosis, with a
range of one to three extra visits per patient (Table 2).
Adherence to schedule was not related to T2 schedule
satisfaction. A comparable percentage of satisfied patients
(20.5 %, 25/122; CSG: 6 less, 7 extra, ESG: 12 extra) and
dissatisfied patients (26.6 %, 4/15; CSG: 1 less, 2 extra,
ESG: 1 extra) did not adhere to the schedule as planned.
Patient Reported Outcome Measures
Of the participants, 83 % completed all questionnaires
at T1 and T2 (CSG: n = 76, ESG: n = 73). PROMs were
analyzed for these 149 participants. Repeated measures
ANOVAs showed one significant between-group effect:
the ESG had significantly lower mean scores on the IES
than the CSG (p = 0.01). The effect size was small
(ES = 0.36). Significant time effects were found on the
CWS, IES, and RAND-36 MCS scores (p = 0.001).
Patients’ CWS and IES mean scores decreased over time,
and the RAND-36 MCS score increased over time. Effect
sizes were small (CWS and RAND-36: ES = 0.41) and
moderate (IES: ES = 0.53). No significant interaction
effects were found (Table 3).
Detection of Recurrences
Total recurrence rate at 1 year after diagnosis was 8.6 %
in the CSG (n = 8) and 8.0 % in the ESG (n = 7,
p = 0.89). Recurrences occurred as loco-regional or in-
transit metastases, regional lymph nodes, second primary
melanomas or distant disease. More recurred (6/
15 = 40 %; CGS: n = 3, ESG: n = 3) than nonrecurred
patients (25/152 = 16.4 %; CGS: n = 9, ESG: n = 16)
paid extra outpatient clinic visits (p = 0.025). Eight of the
15 recurrences (53.3 %) were patient-detected and not
physician-detected (CSG 62.5 %, ESG 42.9 %, p = 0.45).
Seven of the eight self-detecting patients (87.5 %) per-
formed self-inspection at least once a month, whereas in
the physician-detected group this was 57.1 % (p = 0.35).
Self-inspection was performed at least once a month by
78.4 % of the CSG and 65.3 % of the ESG at T2
(p = 0.23; Table 2).
Cost Analysis
Total costs of the hospital based melanoma follow-up in
the first year after primary excision, including detection
and treatment of recurrences and all registered visits, was
only calculated for the 79 patients treated at the UMCG.
The total expense for the ESG (n = 38) was €15,871.11,
Stage-adjusted Reduced Follow-up in Melanoma 2765
TABLE 2 Baseline characteristics (CSG: n = 93, ESG: n = 87) and follow-up related questions; comparison between study groups
Characteristics Conventional schedule Experimental schedule p value
No. % No. %
Gender
Female 42 45.2 % 51 58.6 % 0.071*
Male 51 54.8 % 36 41.4 %
Age (year)
Median, range 55, 23–81 61, 20–85 0.285^
Level of educationa
High 37 39.8 % 31 35.6 % 0.524*
Intermediate 38 40.9 % 33 37.9 %
Low 18 19.4 % 23 26.4 %
Relationship status
With partner 76 81.7 % 76 87.4 % 0.297*
Without partner 17 18.3 % 11 12.6 %
Daily activities
Employed for wages 49 52.7 % 36 41.4 % 0.129*
Not employed for wages 44 47.3 % 51 58.6 %
Presence of co-morbidities
No 62 66.7 % 48 55.2 % 0.114
Yes 31 33.3 % 39 44.8 %
Primary melanoma site
Lower extremity 32 34.4 % 23 26.4 % 0.517*
Upper extremity 17 18.3 % 15 17.2 %
Trunk 34 36.6 % 41 47.1 %
Head/neck 10 10.8 % 8 9.2 %
Breslow thickness (mm)b
Median, range 1.6, 0.3–8.0 1.7, 0.6–7.4 0.733^
\1.00 3 3.2 % 9 10.3 % 0.181*
1.00–2.00 56 60.2 % 42 48.3 %
2.00–4.00 26 28.0 % 28 32.2 %
[4.00 8 8.6 % 8 9.2 %
Ulceration
No 72 77.4 % 64 73.6 % 0.547*
Yes 21 22.6 % 23 26.4 %
AJCC stage
Ib 56 60.2 % 47 54.0 % 0.820*
IIa 19 20.4 % 19 21.8 %
IIb 12 12.9 % 15 17.2 %
IIc 6 6.5 % 6 6.9 %
Schedule satisfactionc (T2)
Yes 60 84.5 % 65 94.2 % 0.064*
No 11 15.5 % 4 5.8 %
Missing 14 13
Reason for schedule dissatisfactionc
Wish for less frequent visits 8 72.7 % 0 0.0 % 0.016**
Wish for more frequent visits 3 27.3 % 4 100.0 %
Frequency of self-inspectionc (T2)
At least once a month 58 78.4 % 48 65.7 % 0.232*
Every 3 months 10 13.5 % 16 21.9 %
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TABLE 2 continued
Characteristics Conventional schedule Experimental schedule p value
No. % No. %
Less than every 3 months 6 8.1 % 9 12.3 %
Missing 11 9
No. of outpatient clinic visits (T2)
Median, range 4, 2–6 2, 1–4 0.001
Less than planned: 10 11.8 % 3 3.7 % 0.051*
-1 visit 8 9.4 % 1 1.2 %
-2 visits 2 2.4 % 2 2.4 %
According to assigned schedule 63 74.1 % 60 76.9 %
More than planned: 12 14.1 % 19 23.2 % 0.133*
?1 extra visit 8 9.4 % 17 21.3 %
?2 extra visits 4 4.7 % 2 2.5 %
Reasons extra outpatient clinic visit
Physical symptoms 9 56.3 % 11 52.4 % 0.956*
Anxiety 6 37.5 % 9 42.9 %
Other 1 6.2 % 1 4.7 %
Extra GP consultationsc (T2)
No 68 80.0 % 71 86.6 % 0.255*
Yes 17 20.0 % 11 13.4 %
1 Melanoma-related visit 16 18.8 % 10 12.2 % 0.498*
2 Melanoma-related visits 1 1.2 % 1 1.2 %
Total extra visits T2 (hospital ? GP)
1 Extra visit 20 23.5 % 19 23.3 % 0.930*
2 Extra visits 5 5.9 % 4 4.9 %
3 Extra visits 1 1.2 % 2 2.4 %
Recurrence
Total 8 8.6 % 7 8.0 % 0.893*
Locoregional 1 12.5 % 0 0.0 %
In transit 1 12.5 % 1 14.3 %
Regional lymph nodes 2 25.0 % 2 28.6 %
Distant 3 37.5 % 1 14.3 %
Second primary melanoma 1 12.5 % 3 42.9 %
Detection of recurrence
Patient 5 62.5 % 3 42.9 % 0.447*
Specialist/NP 3 37.5 % 4 57.1 %
Cause of death
Other cause 1 1.1 % 1 1.2 % 0.522**
Melanoma-relatedd 2 2.2 % 1 1.2 %
Hospital costs (1 year, UMCG) n = 41 n = 38
Total (in Euros), based on: € 31,240.67 € 15,871.11
Follow-up visits € 20,325.88 € 11,127.17
By NP € 141.20 n = 4 € 176.50 n = 5
By specialist € 18,427.21 n = 175 € 8,873.65 n = 83
Telephone consultation € 1,757.47 n = 22 € 2,077.02 n = 26
Diagnostics € 6,651.91 € 1,349.67
Laboratory testing € 318.09 n = 2 – –
Ultrasonography € 729.66 n = 5 € 228.40 n = 1
CT-scan € 836.89 n = 4 – –
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with a mean of €417.66 per patient, and €31,240.67 for the
CSG (n = 41), with a mean of €761.97 per patient. This
demonstrates a mean cost reduction of 45 % (€344.31,
95 % CI 85.9-602.7, p = 0.01) per patient in the ESG. The
differences in number of outpatient clinic visits, and the
type of diagnostics and surgeries performed, are presented
in Table 2. Expenses incurred for comorbidities or GP
consultations were not taken into account in this
calculation.
DISCUSSION
The MELFO study is the first randomized, clinical trial
on the subject of follow-up frequency in AJCC stage IB-II
melanoma patients. The results provide evidence that the
frequency of follow-up visits in these melanoma patients
can be reduced, because neither anxiety, cancer worry,
stress response symptoms, and mental health, nor detection
of recurrences and second primaries, were negatively
affected by a reduced follow-up surveillance schedule.
Besides, this is accompanied with 45 % cost reduction of
overall melanoma care and outpatient clinic visits.
Patients’ mental well-being was similar in both groups
or even better in the group with a reduced follow-up
schedule. Specifically, levels of anxiety, cancer worry, and
mental health-related quality of life were comparable in the
study groups, and significantly reduced stress response
symptoms were reported by the experimental group that
received low-intensity follow-up surveillance. A possible
explanation for this last finding might be that high-intensity
follow-up surveillance can provoke stress rather than
provide assurance. Mixed feelings of melanoma patients
regarding follow-up have previously been described, with
the majority of patients thinking follow-up visits were
worthwhile, but half found them anxiety provoking also.18
Stress response symptoms and cancer worry decreased
significantly over the first year of follow-up and patients’
mental well-being improved in both groups, possibly
because patients became accustomed to having melanoma
or due to the prolonged disease-free time after diagnosis
and treatment. These results support our hypothesis that a
reduced follow-up schedule does not negatively affect
melanoma patients’ mental well-being.
The clinicopathologic characteristics of the MELFO
study group are representative for the Dutch melanoma
population.31 Recurrence rate after 12 months follow-up
was approximately 9 % in both study groups. In literature,
recurrence rates for AJCC stage IB-II patients are descri-
bed from 18 to 45 % with a median time to detection of
28 months.21 Patient-detected recurrences for stage I-III
melanoma are reported to be 60–75 %.12,22,24,32 Of the
small number of recurrences and second melanomas in the
first year after diagnosis in this study, slightly more than
half was patient-detected (53 %). The proportion of
patients performing self-inspection at least once a month
was higher in the patient-detected group, emphasizing the
importance of patient education in relation to the detection
of recurrences.
Schedule satisfaction was high in both groups, sug-
gesting patients might not have a preference for a certain
surveillance schedule but rely on the recommendations of
their clinician. Almost a third of the patients reported that
TABLE 2 continued
Characteristics Conventional schedule Experimental schedule p value
No. % No. %
PET/CT-scan € 2,468.83 n = 2 – –
Bone scan – – € 344.18 n = 1
Pathology: biopsy/cytology € 2,298.44 n = 17 € 777.09 n = 7
Surgery € 4,262.88 € 3,394.27
Melanoma related € 1,424.25 n = 4 € 2,167.44 n = 2
Benign skin lesion € 2,838.63 n = 5 € 1,226.83 n = 4
Total per patient, mean ± SD €761.97 ±683.37 € 417.66 ±452.74 0.010^
AJCC American Joint Committee on Cancer; GP general practitioner; NP nurse practitioner; UMCG University Medical Center Groningen; T2
after 1-year follow-up
T2: 167 patients included in analyses (CSG: n = 85, ESG: n = 82)
a Highest level of education completed (high: high vocational education, university; intermediate: secondary vocational education, high school;
low: elementary school, low vocational education)
b Categories based on the publication of Hollestein et al. 31
c Self-designed questions
d Also included in the number of recurrences
Level of significance p\ 0.05, printed in bold. * v2 test, ^ Independent student t test, ** cell count too low to perform valid v2 test
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they paid extra melanoma-related visits to the specialist or
GP, demonstrating that some patients take action when
they suspect a recurrence or experience anxiety, regardless
of the assigned schedule.
As the prevalence of melanoma continues to rise, the
intensity of surveillance strategies becomes important in
the context of contemporary resource use. Melanoma fol-
low-up is associated with a major financial burden.32,33
With the increasing cost-consciousness in current health-
care, the mean cost reduction of 45 % per patient per year
found in the MELFO study is considerable.
This study was limited by the number of patients
included. According to the power analysis 89 patients were
needed in each study group; however, 87 were assigned to
the ESG. Nevertheless, because no differences or trends
were found between the groups, these two patients would
not have made a significant difference. Also, the number of
patients who completed all questions in the PROMs was
less than required. However, refusal (13 %) and dropout
(7 % for follow-up and 17 % for PROMS) rates were
rather low. Lastly, calculation of costs was only possible of
patients treated at a University Medical Center and may be
slightly different from costs made in smaller hospitals.
Most current guidelines on follow-up frequency are
based on low-level evidence, with unknown impact on
patients’ mental well-being.8, 9 Several potential benefits of
reducing the existing frequency of follow-up visits for
AJCC stage I-II melanoma patients have been proposed.
According to these observational studies and in line with
the present RCT, low-intensity surveillance strategies seem
more efficient and do not appear to adversely affect
patients’ clinical outcomes.17,24,32,34–36 A survey con-
ducted among melanoma specialists in Australia concluded
that extended intervals may even encourage patients to
return immediately in case of a suspicious lesion, rather
than waiting for their next scheduled appointment.16 All
MELFO patients were educated about monthly self-in-
spection of the skin and regional lymph nodes, increasing
patients’ ability to detect a possible recurrence or second
primary.12,23,37 More patients suspecting a recurrence paid
a visit outside of the assigned schedule than those not
suspecting a recurrence, underlining the relevance of pro-
viding patient-education materials.23
CONCLUSIONS
Stage-adjusted reduced follow-up surveillance for AJCC
stage IB-II melanoma patients does not appear to affect
adversely patients’ mental well-being and the detection of
recurrences and is economically favorable compared to
currently conducted high-intensity surveillance. These
results suggest that lower-intensity surveillance may be
safely recommended in evidence-based melanoma follow-
up guidelines. Prolonged follow-up regarding the effect of
a reduced surveillance schedule is necessary to strengthen
this recommendation. In addition, all surveillance pro-
grams should emphasize the importance of patient
education at diagnosis to increase the ability of patients to
perform self-inspection of their skin and lymph node
bearing areas for the timely detection of recurrences.
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TABLE 3 Descriptives of patient-reported outcome measures at baseline (T1) and 1 year (T2), comparison over time and between study groups
Questionnaire Study group T1 mean (SD) T2 mean (SD) ANOVA
STAI-S Conventional 31.4 (8.8) 31.0 (9.9) F = 0.4; p = 0.54 (group)
Experimental 31.3 (8.0) 29.5 (8.8) F = 3.3; p = 0.07 (time)
F = 1.5; p = 0.23 (interaction)
CWS Conventional 4.6 (1.5) 4.2 (1.4) F = 2.7; p = 0.10 (group)
Experimental 4.5 (1.6) 3.7 (1.1) F = 14.1; p\ 0.001 (time), ES = 0.41
F = 2.0; p = 0.16 (interaction)
IES Conventional 21.7 (13.9) 14.4 (13.1) F = 6.6; p = 0.01 (group), ES = 0.36
Experimental 14.8 (13.4) 9.9 (12.0) F = 34.7; p\ 0.001 (time), ES = 0.53
F = 1.4; p = 0.25 (interaction)
RAND-36 MCS score Conventional 49.7 (11.4) 52.5 (8.8) F = 0.25; p = 0.62 (group)
Experimental 49.3 (10.9) 54.3 (7.6) F = 24.5; p\ 0.001 (time), ES = 0.41
F = 2.0; p = 0.16 (interaction)
T1 at inclusion; T2 after 1-year follow-up; STAI-S State-Trait Anxiety Inventory-State (range 20–80); CWS cancer worry scale (range 3–12); IES
impact of event scale (range 15–75); MCS mental component summary (standardized mean 50); F F-statistic; ES effect size
Number (n) varies due to missing answers: STAI-S; n = 144 (75/69), CWS; n = 143 (74/69), IES; n = 116 (58/58), RAND-36; n = 149 (76/
73). Level of significance p\ 0.05, printed in bold
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follow-up study in melanoma patients in England, which is performed
at the Norfolk and Norwich University Hospital. The goal of these
studies is to gain insight into the optimal follow-up schedule of
melanoma patients in the Netherlands and England.
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